Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
preservative: sorbic acid, flavoring, color: carmine
Sickle Cell Disease Management includes hydroxyurea (first-line disease-modifying agent for HbSS/HbS), FDA-approved newer agents (crizanlizumab for vaso-occlusion prevention, voxelotor for hemolysis), chronic transfusion therapy for stroke prevention, and hematopoietic stem cell transplant (HSCT) as the only current curative option
Higher risk of secondary causes
This brief aims to highlight how patent abuse is a key tool enabling the pharmaceutical industry to carry out its financialized business model that perpetuates structural health inequities, particularly among communities of color
